Science Publications

Recent Publications

Nephroprotective Effects of Cilastatin in People at Risk of Acute Kidney Injury: A Systematic Review and Meta-analysis

The study reinforces the clinical relevance of cilastatin, a well-established inhibitor of renal dipeptidase-1 (DPEP1), demonstrating a strong human safety profile and consistent protection against AKI across diverse patient populations.

Abstract

The analysis included more than 1,500 participants from multiple randomized and observational studies involving high-risk clinical settings, including antibiotic-, chemotherapy-, and contrast-associated kidney injury.

Cilastatin treatment was associated with up to a 74% lower risk of AKI, underscoring its potential as a nephroprotective therapy for patients exposed to nephrotoxic drugs or procedures.

Dr. James MD PhD (University of Calgary), who also ...

IL-32 Is a Lipid Droplet-Associated Mediator of Tubular Injury in Diabetic Kidney Disease

The findings provide the scientific foundation for Arch Biopartners’ new CKD platform, expanding the Company’s kidney therapeutics pipeline beyond acute injury to chronic disease.

Overview

The research published in JASN shows that the inflammatory protein IL-32 localizes to lipid droplets in kidney tubular cells, where it drives mitochondrial dysfunction contributing to injury in DKD. This is the first evidence that lipid droplets function as inflammatory platforms linking metabolic stress to progressive kidney damage.

In preclinical models, blocking IL-32 reduced tubular injury, while treatment with the SGLT2 inhibitor canagliflozin lowered IL-32 expression, underscoring the immediate clinical relevance of ...

Multicentre, randomised, double-blind, placebo-controlled, proof of concept study of LSALT peptide as prevention of acute respiratory distress syndrome and acute kidney injury in patients infected with SARS-CoV-2 (COVID-19)

The results of the Phase II trial provided first-ever evidence validating Dipeptidase-1 (DPEP1) as a mediator of organ inflammation and therapeutic target in humans. In addition, LSALT peptide was well tolerated with no safety issues related to the drug.

The Phase II trial was an international, multicenter, randomized, double-blind, placebo-controlled, proof of concept study of LSALT peptide for the prevention of organ inflammation such as acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI) in hospitalised patients infected with SARS-CoV-2. The exploratory, adaptive trial was initiated in the early stages of the global pandemic to ...

Contact Arch Biopartners
Stay connected!

Subscribe for email updates

Get email alerts when news is published
Please check the options for Investor News and Press releases to receive customized email alerts.

Publications Archives